Table 1.
Demographic, virological, and clinical features of IFN-α-treated patients (cohort 1)
| Variable | All | SVR (%) | NR (%)* | P | |
|---|---|---|---|---|---|
| No. of patients | 284 | 98 (34.5) | 186 (65.5) | ||
| Race, no. | CA | 213 | 90 (42.3) | 123 (57.7) | <0.001 |
| AA | 71 | 8 (11.3) | 63 (88.7) | ||
| Sex, no. | Female | 103 | 44 (42.7) | 59 (57.3) | 0.028 |
| Male | 181 | 54 (29.8) | 127 (70.2) | ||
| Age, years† | 48.8 ± 8.5 | 47.2 ± 8.9 | 49.7 ± 8.2 | 0.017 | |
| ALT, units/liter† | 112.8 ± 83.9 | 122.8 ± 99.9 | 107.3 ± 73.4 | 0.222 | |
| Viral titer, log10(copies/ml)† | 6.2 ± 0.6 | 6.1 ± 0.7 | 6.3 ± 0.5 | 0.016 | |
| Virus genotype, no. | 1 | 223 | 53 (23.8) | 170 (76.2) | |
| Other | 53 | 40 (75.5) | 13 (24.5) | <0.001 | |
| Nonclassified | 8 | 5 (62.5) | 3 (37.5) | ||
| Histological grade, no. | Minimal to mild (≤7) | 57 | 27 (47.4) | 30 (52.6) | |
| Moderate to severe (>7) | 178 | 58 (32.6) | 120 (67.4) | 0.044 | |
| No biopsy | 49 | 13 (26.5) | 36 (73.5) | ||
| Fibrosis stage, no. | Minimal to mild (0, 1) | 122 | 57 (46.7) | 65 (53.3) | |
| Moderate to severe (3, 4) | 113 | 28 (24.8) | 85 (75.2) | 0.001 | |
| No biopsy | 49 | 13 (26.5) | 36 (73.5) |
P values in boldface are significant. ALT, alanine aminotransferase.
*Includes relapse after stopping treatment and no response during treatment.
†Data are expressed as mean ± SD.